Abhijit (Hrsg.) Ray

Obstructive Airway Diseases

Role of Lipid Mediators

Buch

This book describes airway diseases, prevalence, pathophysiology, and therapeutic options, then explores the link between lipid metabolites and airway disease. It examines the cellular lipid metabolic machinery carefully and evaluates the research for and against important constituents to act as targets for drug discovery for treating airway diseases. It covers preclinical drug discovery efforts around well known and not so conventional lipid targets. It discusses molecules that have gone into clinical trial and become successful drugs as well as those that were not successful, giving readers an understanding of the drug discovery approach wh… Mehr

CHF 269.00

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen

V105: Folgt in ca. 15 Arbeitstagen

Produktdetails

Weitere Autoren: Srivastava, Punit Kumar (Hrsg.)

ISBN: 978-1-4398-5140-1
EAN: 9781439851401
Produktnummer: 23095061
Verlag: Taylor & Francis Inc
Sprache: Englisch
Erscheinungsjahr: 2011
Seitenangabe: 381 S.
Masse: H23.4 cm x B15.6 cm x D0.0 cm 635 g
Abbildungen: N/A; N/A; 26 Tables, black and white; 78 Illustrations, black and white
Gewicht: 635
Sonstiges: Postgraduate, Research & Scholarly

Über den Autor

Abhijit Ray has worked in human trials with molecules designed to treat airway inflammation associated with asthma and COPD and has published more than 60 articles in peer-reviewed journals. He has been the senior director and head of biology research at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. As a member of the drug discovery team, he manages a group of 60 scientists engaged in discovery research for drugs in the areas of infectious and inflammatory diseases.Punit Srivastava has been a group leader of biology at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. He was a member of the drug discovery group of Ranbaxy Laboratories Ltd. from 2004 to June 2010 and has worked for more than six years in drug discovery research, which has resulted in one molecule entering human trial for COPD. He has published more than 15 articles in peer-reviewed journals and filed at least six patents. As a member of the drug discovery team at Daiichi Sankyo, he is leading projects in the area of inflammation.